Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2004

View Archived Issues

Safety labeling changes for mifepristone

Pivotal study of MyVax Personalized Immunotherapy recommended to continue

Zambon withdraws from monoingredient asthma project

Positive phase II data with HspE7 in high grade cervical dysplasia

Lilly advances Isis collaborative compound into phase I

Positive findings in pilot pharmacokinetic study of Intraject sumatriptan

Preliminary results of ReceptoPharm's MS drug in microarray studies

PHER-O2 completes animal toxicity and efficacy trials at U. of Alberta

Bristol-Myers Squibb highlights pipeline progress

VivaGel well tolerated in phase I study

Approvable letter for Yaz

Anxiolytic and antidepressant effects of a novel CRF1 receptor antagonist from Ono

New combinations comprising roflumilast

Scientists at Arachnova patent topical buspirone formulations for skin conditions

Novel series of VEGFR/KDR inhibitors covered by Amgen patent

NH3 exchange inhibitors and their use described by Aventis

Researchers at Bayer describe new CCR3 antagonists

New compounds with RFRP antagonist properties

Antitumor effects and safety profile of LEP-ETU in advanced cancer

Good toxicity profile of single and multiple doses of TC-2403-12 in healthy volunteers

Effective pain control achieved with Ionsys in women after gynecological surgery

Darifenacin shows efficacy in the treatment of women with overactive bladder

Efaproxiral improves survival after WBRT in patients with brain metastasis

First clinical data reported for IGN-311 in solid tumors overexpressing Lewis Y antigen

New clinical data on the antiviral efficacy of entecavir in hepatitis B

First market introductions of strontium ranelate for postmenopausal osteoporosis

Third generation antifolate selected for preclinical development for the treatment of malaria

NEU-2000 effective in models of stroke, amyotrophic lateral sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...